Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection

Cancer Gene Ther. 2007 Apr;14(4):364-71. doi: 10.1038/sj.cgt.7701018. Epub 2007 Jan 19.

Abstract

Dendritic cell (DC) expansion is regulated by the hematopoietic growth factor fms-like tyrosine kinase 3 ligand (Flt3L). DCs are critical to the control of tumor growth and metastasis, and there is a positive correlation between intratumoral DC infiltration and clinical outcome. In this report, we first demonstrate that single intravenous (i.v.) injections of adenovirus (Adv)-Flt3L significantly increased splenic dendritic, B, T and natural killer (NK) cell numbers in both normal and mammary tumor-bearing mice. In contrast, the numbers of DCs and T cells infiltrating the tumors were not increased. Consistent with the minimal effect on immune cell infiltration, i.v. Adv-Flt3L injections had no therapeutic activity against orthotopic mammary tumors. In addition, we noted tumor and Adv-Flt3L expansion of Gr1(+)CD11b(+) immature myeloid suppressor cells (IMSCs), which may inhibit the therapeutic efficacy of Adv-Flt3L-expanded DCs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Dendritic Cells / immunology
  • Female
  • Genetic Therapy*
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Injections, Intravenous
  • Lymphocyte Count
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Mammary Neoplasms, Animal / therapy*
  • Membrane Proteins / genetics*
  • Mice
  • Mice, Inbred BALB C
  • Spleen / immunology*
  • T-Lymphocytes / immunology*
  • Treatment Failure

Substances

  • Membrane Proteins
  • flt3 ligand protein